AVRO VS YS Stock Comparison

Performance

AVRO
100/100

AVRO returned 78.43% in the last 12 months. Based on SPY's performance of -12.98%, its performance is above average giving it a score of 100 of 100.

YS
10/100

YS returned -94.73% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVRO
88/100

4 analysts offer 12-month price targets for AVRO. Together, they have an average target of 0, the most optimistic target put AVRO at 0 within 12-months and the most pessimistic has AVRO at 0.

YS

"Analyst Price Targets" not found for YS

Technicals

AVRO
25/100

AVRO receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

YS

"Technicals" not found for YS

Earnings

AVRO
10/100

AVRO has missed earnings 13 times in the last 20 quarters.

YS

"Earnings" not found for YS

Profit

AVRO
10/100

Out of the last 20 quarters, AVRO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

YS

"Profit" not found for YS

Volatility

AVRO
25/100

AVRO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

YS
23/100

YS has had a lower than average amount of volatility over the last 12 months giving it a score of 22 of 100.

All score calculations are broken down here to help you make more informed investing decisions

AVROBIO, Inc. Common Stock Summary

Nasdaq / AVRO

Healthcare

Biotechnology

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

YS Biopharma Co., Ltd. Ordinary Shares Summary

Nasdaq / YS

Healthcare

Biotechnology

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Power up your portfolio